您好，欢迎访问中国热带农业科学院 机构知识库！
中国热带农业科学院机构知识库

全部

  • 全部
  • 标题
  • 学者
  • 机构
  • 关键词

Doxorubicin prodrug-based nanomedicines for the treatment of cancer

文献类型： 外文期刊

作者： Zhao, Haibo 1 ; Yu, Jing 2 ; Zhang, Renshuai 1 ; Chen, Pengwei 3 ; Jiang, Hongfei 1 ; Yu, Wanpeng 4 ;

作者机构： 1.Qingdao Univ, Qingdao Univ, Canc Inst Affiliated Hosp, Qingdao 266071, Peoples R China

2.Univ Hlth & Rehabil Sci, Qingdao Hosp, Qingdao Municipal Hosp, Qingdao 266071, Peoples R China

3.Chinese Acad Trop Agr Sci, Inst Trop Biosci & Biotechnol, Hainan Key Lab Res & Dev Nat Prod Li Folk Med, Haikou 571101, Peoples R China

4.Qingdao Univ, Qingdao Med Coll, Qingdao 266071, Peoples R China

关键词： Doxorubicin; Prodrug; Nanomedicine; Stimuli responsive; Cancer therapy; Antitumor

期刊名称：EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY （ 影响因子：6.7； 五年影响因子：6.5 ）

ISSN： 0223-5234

年卷期： 2023 年 258 卷

页码：

收录情况： SCI

摘要： The chemotherapeutic drug of doxorubicin (DOX) has witnessed widespread applications for treating various cancers. DOX-treated dying cells bear cellular modifications which allow enhanced presentation of tumor antigen and neighboring dendritic cell activation. Furthermore, DOX also facilitate the immune-mediated clearance of tumor cells. However, disadvantages such as severe off-target toxicity, and prominent hydrophobicity have resulted in unsatisfactory clinical therapeutic outcomes. The effective delivery of DOX drug molecules is still challenging despite the rapid advances in nanotechnology and biomaterials. Huge progress has been witnessed in DOX nanoprodrugs owing to their brilliant benefits such as tumor stimuli-responsive drug release capacity, high drug loading efficiency and so on. This review summarized recent progresses of DOX prodrug-based nanomedicines to provide deep insights into future development and inspire researchers to explore DOX nanoprodrugs with real clinical applications.

  • 相关文献
作者其他论文 更多>>
置顶
购物车
反馈

© 京ICP备09089781号-29 主办单位：中国热带农业科学院

学术资源： 中国农业科学院 农业专业知识服务系统 农科联盟资源共建共享平台 中国农业科技文献与信息服务平台 中国农业期刊集成服务平台